Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial ...

BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking ...

Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M ...

Healthcare firms have done comparatively well in an otherwise subdued U.S. IPO market in 2024, which analysts touted as a comeback year for public offerings. The Richmond, California-based company ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg ...

A Quick Take On BioAge Labs, Inc. BioAge Labs, Inc. (BIOA) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a clinical ...

queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara Therapeutics, ...

"BioAge's IPO could serve as a bellwether for the sector, potentially catalyzing further investment and innovation," Kazi Helal, Ph.D., senior biotech analyst at PitchBook, told Fierce Biotech in ...

NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.

The proposed IPO comes months after BioAge raised $170 million in a funding round led by life sciences investment firm Sofinnova Investments. The company lost $26.6 million in the first half of ...